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AMPK, and HADHB mRNA expression were increased compared with control mice ( Figure 1B ). However, we did not observe differences in hepatic ABCA1 and CROT protein expression ( Figure 1C ). In agreement with this observation, we did not also observe differences in total cholesterol, HDL-C, and triglyceride levels among treatments ( Figure 1D-1F ), suggesting that anti-miR-33 therapy fails to increase hepatic ABCA1 expression and circulating HDL levels in mice fed a WD. The cholesterol distribution in different lipoproteins was also not affected by anti-miR-33 treatment ( Figure 1G ). These results might be explained by the reduced expression of miR-33 in the liver of mice fed a WD compared with mice fed a chow diet. 5 Despite the absence of changes in HDL-C between treatments, we found that atherosclerotic lesion areas were significantly reduced in the aortic roots of mice injected with anti-miR-33, compared with PBS and Ctrl antisense oligonucleotides (ASO) groups (Figure 2A and 2B). Further analysis of the atheromata revealed no differences in the fibrous cap and necrotic core between treatments ( Figure 2A-2C ). However, CD68 staining revealed a decrease in the macrophage content in the proximal aortas of mice injected with anti-miR-33 oligonucleotides compared with the PBS and Ctrl ASO-treated mice ( Figure 2D ).
We further analyzed the potential mechanism that mediates atheroprotection in anti-miR-33-treated mice. It has been previously shown that HDL functionality has a strong inverse association with atherosclerotic vascular disease independent of the total plasma HDL-C. 7 Therefore, we analyzed the HDL functionality by assessing its ability to promote cellular cholesterol efflux and to protect endothelial cells (ECs) from cytokine-induced inflammation. As seen in Figure IIA in the online-only Data Supplement, HDL isolated from anti-miR-33-treated mice induced greater macrophage cholesterol efflux than did HDL isolated from Ctrl ASO-treated mice. In addition to cholesterol efflux, we also assessed the effect of HDL isolated from both groups of mice on tumor necrosis factor-induced inflammation in human aortic ECs. As expected, vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1) were significantly downregulated when we treated human aortic ECs with HDL, but no differences were noted between HDL isolated from both groups of mice ( Figure IIB in the online-only Data Supplement). The reasons behind the increased cholesterol efflux capacity of HDL from mice treated with anti-miR-33 remain unclear and will require further investigation.
Finally, we analyzed the expression of inflammatory cytokines, adhesion molecules, and matrix remodeling enzymes in the aortas from the 3 groups of mice. In contrast to the results observed in the liver, anti-miR-33 therapy significantly increased the expression of ABCA1 at mRNA and protein levels (Figure 2E and 2F) . Moreover, we observed an upregulation of MMP-2, COL1A-1, and COL3A-1 suggesting that miR-33 might also be important in regulating plaque remodeling ( Figure 2E ). Similar to the results observed in the miR-33 −/− Apoe −/− mice, 8 we found a significant increase in the proinflammatory cytokines, TNFα and IL-1β, whereas IL-6 expression was reduced ( Figure 2E ). In agreement with the reduced macrophage content observed in atherosclerotic plaques from mice treated with anti-miR-33 in regression studies, the expression of CD68 and MAC-2 was significantly reduced in this group of mice ( Figure 2E ). To analyze whether the macrophage infiltration correlated with reduced levels of adhesion molecules in the aorta, we analyzed the expression of ICAM-1, VCAM-1, and ESEL. As shown in Figure 2E , anti-miR-33 treatment reduced significantly ICAM-1, VCAM-1, and ESEL expression indicating that miR-33 might regulate the expression of these molecules in ECs, thereby controlling macrophage infiltration in the artery wall. To elucidate whether the anti-inflammatory effect of anti-miR-33 therapy in the artery wall is mediated by a direct effect of miR-33 on EC activation, we transfected human aortic ECs with anti-miR-33 oligonucleotides and stimulated them with TNF for 6 hours. The results show that miR-33 inhibition did not reduce significantly the expression of ICAM-1 and VCAM-1 compared with cells treated with Ctrl ASO, suggesting that the anti-inflammatory effect of anti-miR-33 oligonucleotides is likely mediated by increasing macrophages cholesterol efflux and reducing their accumulation in the artery wall ( Figure IIC in the online-only Data Supplement).
Discussion
Previous studies by Rayner et al 6 demonstrated that a 2′-fluoro/2′-methoxyethyl-modified anti-miR-33 was effective in an atherosclerosis regression model. 6 In Ldlr −/− mice with established atherosclerotic plaques, anti-miR-33 treatment resulted in significant reduction in plaque size and elevated circulating HDL-C. In contrast, here we reported that anti-miR-33 failed to increase HDL-C when mice were fed a WD. The mechanism by which the anti-miR-33 did not increase circulating HDL-C in WD-fed animals remains unclear and requires further investigation. Even though the circulating HDL-C levels were the same in all experimental groups, we observed a significant reduction in atherosclerotic plaque size in mice treated with miR-33 ASO. Importantly, the cholesterol efflux capacity of HDL isolated from mice treated with anti-miR-33 was significantly higher compared with HDL isolated from Ctrl ASO mice. In addition to the increased functionality of the HDL particles, these results also suggest that the atheroprotective effects of miR-33 ASO might be in part mediated by their effect in the artery wall. While this article was under preparation, Horie et al 8 reported that miR-33 −/− Apoe −/− have decreased atherosclerosis compared with Apoe −/− mice. To determine the contribution of miR-33 in monocytes/macrophages, the authors used bone marrow transplantation experiments. The results demonstrated that miR-33 was important in regulating ABCA1 expression in macrophages and lipid accumulation in the artery wall. However, the deficiency of miR-33 in myeloid cells did not reduce atherosclerotic plaque size as expected. This observation suggests that the antiatherosclerotic effect of anti-miR-33 might be mediated by another cell type in the artery wall, such as ECs and vascular smooth muscle cells. Indeed, absence of ABCA1 and ABCG1 in ECs leads to endothelial dysfunction in mice fed a high-cholesterol diet. 9 Therefore, tissue-specific null mice for miR-33 will be important to determine the contribution of miR-33 in hepatocytes, macrophages, and endothelial and smooth muscle cells during atherogenesis.
While this study was under revision, another group reported that anti-miR-33 therapy fails to increase circulating HDL-C levels and to slow the progression of atherosclerosis in Ldlr −/− mice, 10 in contrast to our results. However, there are several important differences between the 2 studies. First, although the 2′-fluoro/2′-methoxyethyl anti-miR has been shown in this study and in the previous publication 6 to target miR-33 and regulate gene expression in atherosclerotic plaque and whole aorta, the effect of the locked nucleic acid-modified oligonucleotide used in the Marquart et al 10 study was not examined in the artery wall. It is possible that the locked nucleic acid anti-miR was not effectively taken up in the plaque macrophages. The second important difference between the studies is the cholesterol concentration in the diets. In our study, the WD contained 0.3% cholesterol, whereas Marquart et al 10 used 1.25%, a more severe model of atherosclerosis. This is an important point because it is expected that miR-33 levels are reduced as cellular cholesterol content increases, and high dietary cholesterol concentration may reduce miR-33 expression to levels where the anti-miR-33 therapy could not have further effect in the liver and peripheral tissues. Finally, Marquart et al 10 observed that anti-miR-33 therapy increases plasma triglyceride content, whereas we did not find differences in our study. Altogether, these studies suggest that different oligonucleotide chemistry and cholesterol content in the diet could be relevant to the efficacy of anti-miR-33 therapy. Future studies dissecting the relative importance of these variables to the phenotype will be important to clarify the full therapeutic potential for miR-33 targeting.
